Alivas
Latest round
- Series B
Last raised
- Apr 2023
Total raised
- $5.3M
Investors
- 4
About Alivas
Alivas Inc.Founded in 2017 and headquartered in Tokyo, Japan, Alivas Inc. focuses on the creation of medical devices for chronic constipation treatment. Tomoyuki Tajima serves as both the founder and CEO.Alivas Inc. develops innovative medical devices specifically designed to treat refractory chronic constipation, impacting over 10 million people in Japan. Their primary product is a novel therapeutic device, developed in collaboration with institutions such as Stanford University and the University of Tokyo, intended for patients resistant to conventional pharmacological treatments.Alivas Inc.In April 2023, Alivas Inc. The company plans to introduce new products that address chronic constipation and expand into additional markets beyond Japan.
Who invested in Alivas
4 investors across 3 rounds
See all investors in Alivas
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alivas
Who invested in Alivas?
Alivas has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alivas raised?
Alivas has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Alivas last raise money?
Alivas's most recent round on record is a Series B, in Apr 2023.
What does Alivas do?
Alivas is a medical devices & equipment company.
Where is Alivas headquartered?
Alivas is headquartered in Tokyo, Japan.
Which VCs invest in companies like Alivas?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back medical devices & equipment companies at Alivas's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series B
Raising like Alivas? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.